论文部分内容阅读
目的：比较不同组织细胞中端粒酶ＲＮＡ（ｈＴＲ）的序列，建立以ｈＴＲ为基础的肿瘤诊断与治疗新技术。方法：采用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）技术从人肝癌细胞株（ＨｅｐＧ２）中扩增出了ｈＴＲ部分ｃＤＮＡ序列，并通过电泳的方法鉴定了其特异性。通过分子克隆技术将上述产物插入Ｔ－质粒后转化入大肠杆菌ＪＭ１０９中，经聚合酶链反应（ＰＣＲ）鉴定了插入片段的特异性及方向，最后采用自动ＤＮＡ序列分析仪分析了上述插入片段的核酸序列，并比较了与已知的人２９３细胞ｈＴＲ的同源性。结果：人肝癌细胞株ＨｅｐＧ２的ｈＴＲ序列（４７～１７４）与２９３细胞完全同源。结论：ｈＴＲ可以作为肿瘤基因诊断和治疗的新靶点
OBJECTIVE: To compare the sequence of telomerase RNA (hTR) in different tissue cells and establish a new hTR-based tumor diagnosis and therapy technique. METHODS: hTR partial cDNA sequence was amplified from human hepatoma cell line (HepG2) by reverse transcription polymerase chain reaction (RT-PCR) and its specificity was identified by electrophoresis. The above product was inserted into the T-plasmid by molecular cloning and transformed into E. coli JM109. The specificity and orientation of the insert were identified by polymerase chain reaction (PCR). Finally, the above insert was analyzed using an automatic DNA sequencer. Nucleic acid sequences and comparisons of hTR homology with known human 293 cells. Results: The hTR sequence (47-174) of human hepatoma cell line HepG2 was completely homologous to 293 cells. Conclusion: hTR can be used as a new target for tumor gene diagnosis and treatment